Sage Therapeutics strikes $3.1bn licensing deal with biogen for depression and neurological disorder treatments

Sage Therapeutics has entered into a high-stakes global collaboration and licensing agreement with Biogen, valued at up to $3.1 billion, aimed at advancing two promising ... Read More